SBOTF Stock UPDATES Stellar Biotech Inc (SBOTF) 2.0950 08/26/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Stellar Biotech Inc (SBOTF) 2.0950 $SBOTF

Stellar Biotechnologies Reports Third Quarter 2014 Financial Results and Recent Corporate Developments
Marketwire - Thu Jul 10, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), a leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets, has reported financial results for the third quarter and nine months ended May 31, 2014, and provided operational highlights.

Stellar Biotechnologies Presenting Today at 2014 TSX Venture 50(R) Spotlight Event
Marketwire - Tue Apr 01, 8:03AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announced that the company is presenting today at the 2014 TSX Venture 50(R) Spotlight Event being held in Calgary, Canada.

Stellar Biotechnologies Presents Poster on KLH Achievements at Gordon Research Conference
Marketwire Canada - Mon Mar 03, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced the presentation of a poster at the Gordon Research Conference (GRC) on Marine Natural Products, being held March 2-7, 2014 in Ventura, California.

Stellar Biotechnologies to Present at the 26th Annual ROTH Capital Growth Conference
Marketwire Canada - Thu Feb 27, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), a company focused in the immunotherapy arena with world-leading technology in Keyhole Limpet Hemocyanin (KLH) protein, announced today that the Company will present at the 26th Annual ROTH Capital Partners Growth Conference to be held March 9-12, 2014 at The Ritz-Carlton, Laguna Niguel in Dana Point, California.

Stellar Biotechnologies Reports on Annual General and Special Meeting
Marketwire - Tue Feb 18, 8:06AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announces that the Company held its Annual General and Special Meeting of Shareholders (the "Meeting" on Thursday, February 13, 2014 at which all Meeting resolutions were approved. The resolutions passed at the Meeting include the following:

Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.

Stellar Biotechnologies Named 2014 TSX Venture 50(R) Company
Marketwire Canada - Thu Feb 13, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today that the Company has been named to the 2014 TSX Venture 50(R), an exclusive ranking of the top performing companies on the TSX Venture Exchange.

Stellar Biotechnologies Presents KLH Verification Method at Aquaculture America Conference
Marketwire Canada - Wed Feb 12, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today the presentation of a poster at Aquaculture America 2014 (Seattle, February 9-12, 2014), describing a new method for verifying authenticity of Keyhole Limpet Hemocyanin (KLH) product.

Mindoro Welcomes Significant New Investor as Prime Resources Holdings, Inc. Acquires 13.33% of Mindoro's Shares
Marketwire - Fri Jan 17, 7:01AM CST
Mindoro Resources Ltd. (TSX VENTURE: MIO)(ASX: MDO)(FRANKFURT:WKN 906167) ("Mindoro", or "the Company" is pleased to advise that Prime Resources Holdings, Inc. ("PRHI" has acquired approximately 13.33% of Mindoro's issued and outstanding common shares through a secondary trade in the market.

Stellar Biotechnologies, Inc. to Present at Two Investor Conferences in January
Marketwire - Mon Jan 06, 8:15AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that the Company will present at two upcoming investor conferences in January: the Biotech Showcase 2014 in San Francisco and the Noble Financial Capital Markets Tenth Annual Equity Conference in South Florida.

Stellar Biotechnologies Issues Year-End Results and Highlights From 2013
Marketwire Canada - Thu Jan 02, 8:05AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today the filing of its annual report for the fiscal year ended August 31, 2013 and financial results and operational highlights for 2013.

Stellar Biotechnologies, Inc. Announces Meeting and Record Date and Approval of Advance Notice Policy
Marketwire - Fri Dec 27, 6:20PM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that it will hold an annual general and special meeting of shareholders (the "Meeting" on February 13, 2014. The record date for the shareholders entitled to vote at the Meeting has been set as shareholders of record as at the close of business on January 9, 2014.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 113

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 352

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 377

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 225

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Scent Dispensing Solution for Hunting Enthusiasts

Updated Category News Views 168

Introducing a Game-Changing Scent Dispensing System In the world of hunting, attracting game animals can often be a challenge. A new invention, designed specifically for this purpose, promises to make the process much simpler and more efficient. The inventor of this innovative scent dispensing system, THE DRAG LINE PRO, envisioned a better way to utilize a scent drag...

Continue Reading
Corby Spirit and Wine Limited Reports Impressive Fiscal Results

Updated Category News Views 295

Corby Spirit and Wine Limited Announces Strong Fiscal Performance Corby Spirit and Wine Limited, renowned for its position as a leading Canadian manufacturer, marketer, and importer of spirits, has recently unveiled impressive results for its fourth quarter and full-year fiscal 2025. The company demonstrated significant growth in revenue, achieving total revenues of...

Continue Reading
Sezzle Faces Setback as Short-Seller Targets Its Practices

Updated Category News Views 113

Sezzle's Stock Takes a Dramatic Hit Recently, the buy now, pay later (BNPL) provider Sezzle experienced a significant decrease in its stock value. Reports indicate that shares fell over 28.6% in early trading after Hindenburg Research disclosed a short position against the company due to concerns surrounding risky lending practices. Understanding the Short-Selling...

Continue Reading
Exploring the Growth of $1000 in Marsh & McLennan Cos Today

Updated Category News Views 116

Understanding Long-Term Investment in Marsh & McLennan Marsh & McLennan Cos (NYSE: MMC) has established itself as a financial powerhouse, outperforming the market consistently over the past two decades. Investors have experienced an impressive annualized return of 13.31%, showcasing the benefits of long-term investment strategies. The Value of Persistence in Investing...

Continue Reading
Discover Toll Brothers' Latest Luxury Homes at Overbrook Estates

Updated Category News Views 671

Introducing Overbrook Estates by Toll Brothers Toll Brothers, Inc. (NYSE:TOL), a renowned name in luxury homebuilding, excitedly unveils its newest community: Overbrook Estates. This anticipated project is set to grace the Huntersville area, offering homebuyers elegant living in a master-planned environment. Positioned conveniently off Highway 77, this prime location sets...

Continue Reading